15

CLAIMS

- 1. A vaccine composition comprising a major outer membrane protein (MOMP) from Chlamydia in conjunction with a mucosal adjuvant, which induces a MOMP antigen specific TH1-like immune response.
- 5 2. A vaccine as claimed in claim 1 wherein the outer membrane protein is selected from serovar D to K or L.
 - 3. A vaccine as claimed in claim 3 wherein the outer membrane is selected from F, L2, D or E.
- 4. A vaccine as claimed in claim 1 additionally comprising a Chlamydia MOMP
 protein from a different serovar, selected from the group consisting of a serovars
 B, Ba, D, E, L1, F, G, K, L3, A, C, H, I and J.
 - 5. A vaccine as claimed in any of claims 1 to 4 wherein the adjuvant is selected from the group comprising a combination of QS21 and 3 De-O-acylated monophosphocyl lipid A (3D-MPL), mutated heat-labile enterotoxin (mLT) or cholera toxin (CT).
 - 6. A vaccine as claimed in claim 5 wherein QS21 additionally comprises a sterol.
 - 7. A vaccine as claimed in claim 6 wherein the sterol is cholesterol.
 - 8. A vaccine at claimed in claim 7 wherein QS21 is associated with a cholesterol containing lipesome.
- 9. A vaccine as claimed in claim 5 wherein the mucosal adjuvant is LT holotoxin where arginine at position 192 is substituted with glycine (mLT R192 G).
 - 10. A vaccine as claimed in any of claims 1 to 4 wherein the MOMP is the full length mature protein, devoid of the signal sequence.
- 11. A vaccine as ciaimed in any of claims 1 to 4 adapted for oral, or intranasal administration

10

- 12. A vaccine as chaimed in any of claims 1 to 4 adapted for systemic administration.
- 13. A delivery device pre-filled with the vaccine of claim 1, said device being designed to administer the vaccine systemically.
- 14. A vaccine as claimed in any of claims 1 to 4 wherein the outer membrane protein
 is produced in Ω, coli by recombinant DNA technology.
 - 15. A process for the production of a vaccine comprising admixing a mucosal adjuvant with a MOMP from Chlamydia.
 - 16. A method of inducing heterotypic prophylaxis of Chlamydia infection comprising administering to a patient a safe and effective amount of a vaccine composition of claims 1-4.
 - 17. A method of inducing heterotypic prophylaxis of Chlamydia induced infertility comprising administering to a patient a safe and effective amount of a vaccine composition of claims 1-4.